123 related articles for article (PubMed ID: 36306194)
41. [Clinicopathologic characteristics and prognosis of rectal neuroendocrine neoplasms].
Liu T; Liu P; Wu T; Pan Y; Chen G; Wang P; Jiang Y; Wu Y; Wang X
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1015-1019. PubMed ID: 28900992
[TBL] [Abstract][Full Text] [Related]
42. Novel recurrence risk stratification of resected pancreatic neuroendocrine tumor.
Gao H; Liu L; Wang W; Xu H; Jin K; Wu C; Qi Z; Zhang S; Liu C; Xu J; Ni Q; Yu X
Cancer Lett; 2018 Jan; 412():188-193. PubMed ID: 29107104
[TBL] [Abstract][Full Text] [Related]
43. Clinico-morphological analysis of the neuroendocrine neoplasms of the gastroenteropancreatic system.
Delektorskaya VV; Kozlov NA; Chemeris GY
Klin Lab Diagn; 2013 Oct; (10):48-50, 10-3. PubMed ID: 24640093
[TBL] [Abstract][Full Text] [Related]
44. The Postoperative Occurrence or Worsening of Diabetes Mellitus May Increase the Risk of Recurrence in Resected Pancreatic Neuroendocrine Tumors.
de Mestier L; Védie AL; Faron M; Cros J; Rebours V; Hentic O; Do Cao C; Bardet P; Lévy P; Sauvanet A; Ruszniewski P; Hammel P
Neuroendocrinology; 2020; 110(11-12):967-976. PubMed ID: 31791037
[TBL] [Abstract][Full Text] [Related]
45. Variability of the Ki-67 proliferation index in gastroenteropancreatic neuroendocrine neoplasms - a single-center retrospective study.
Shi H; Zhang Q; Han C; Zhen D; Lin R
BMC Endocr Disord; 2018 Jul; 18(1):51. PubMed ID: 30055596
[TBL] [Abstract][Full Text] [Related]
46. Machine learning-based model for prediction and feature analysis of recurrence in pancreatic neuroendocrine tumors G1/G2.
Murakami M; Fujimori N; Nakata K; Nakamura M; Hashimoto S; Kurahara H; Nishihara K; Abe T; Hashigo S; Kugiyama N; Ozawa E; Okamoto K; Ishida Y; Okano K; Takaki R; Shimamatsu Y; Ito T; Miki M; Oza N; Yamaguchi D; Yamamoto H; Takedomi H; Kawabe K; Akashi T; Miyahara K; Ohuchida J; Ogura Y; Nakashima Y; Ueki T; Ishigami K; Umakoshi H; Ueda K; Oono T; Ogawa Y
J Gastroenterol; 2023 Jun; 58(6):586-597. PubMed ID: 37099152
[TBL] [Abstract][Full Text] [Related]
47. Pancreatic neuroendocrine tumors: accurate grading with Ki-67 index on fine-needle aspiration specimens using the WHO 2010/ENETS criteria.
Farrell JM; Pang JC; Kim GE; Tabatabai ZL
Cancer Cytopathol; 2014 Oct; 122(10):770-8. PubMed ID: 25044931
[TBL] [Abstract][Full Text] [Related]
48. Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. The large experience of the Spanish National Tumor Registry (RGETNE).
Martin-Perez E; Capdevila J; Castellano D; Jimenez-Fonseca P; Salazar R; Beguiristain-Gomez A; Alonso-Orduña V; Martinez Del Prado P; Villabona-Artero C; Diaz-Perez JA; Monleon A; Marazuela M; Pachon V; Sastre-Valera J; Sevilla I; Castaño A; Garcia-Carbonero R
Neuroendocrinology; 2013; 98(2):156-68. PubMed ID: 23988576
[TBL] [Abstract][Full Text] [Related]
49. Microenvironment and tumor inflammatory features improve prognostic prediction in gastro-entero-pancreatic neuroendocrine neoplasms.
Milione M; Miceli R; Barretta F; Pellegrinelli A; Spaggiari P; Tagliabue G; Centonze G; Paolino C; Mangogna A; Kankava K; Pusceddu S; Giacomelli L; Corti A; Cotsoglou C; Mazzaferro V; Sozzi G; de Braud F; Pruneri G; Anichini A
J Pathol Clin Res; 2019 Oct; 5(4):217-226. PubMed ID: 31136102
[TBL] [Abstract][Full Text] [Related]
50. Nomogram predicting the risk of recurrence after curative-intent resection of primary non-metastatic gastrointestinal neuroendocrine tumors: An analysis of the U.S. Neuroendocrine Tumor Study Group.
Merath K; Bagante F; Beal EW; Lopez-Aguiar AG; Poultsides G; Makris E; Rocha F; Kanji Z; Weber S; Fisher A; Fields R; Krasnick BA; Idrees K; Smith PM; Cho C; Beems M; Schmidt CR; Dillhoff M; Maithel SK; Pawlik TM
J Surg Oncol; 2018 Apr; 117(5):868-878. PubMed ID: 29448303
[TBL] [Abstract][Full Text] [Related]
51. Somatostatin analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real life.
Faggiano A; Carratù AC; Guadagno E; Tafuto S; Tatangelo F; Riccardi F; Mocerino C; Palmieri G; Damiano V; Siciliano R; Leo S; Mauro A; Tozzi LF; Battista C; De Rosa G; Colao A
Oncotarget; 2016 Feb; 7(5):5538-47. PubMed ID: 26701729
[TBL] [Abstract][Full Text] [Related]
52. [Accurate grading of pancreatic neuroendocrine tumors with Ki-67 index in fine-needle aspiration specimens: a comparative cytologic and histologic study].
He SR; Cui D; Gong H; Zhu YP; Chen L; Hu ST; Liu DG
Zhonghua Bing Li Xue Za Zhi; 2017 Jun; 46(6):393-399. PubMed ID: 28591986
[No Abstract] [Full Text] [Related]
53. Ki-67 grading of nonfunctioning pancreatic neuroendocrine tumors on histologic samples obtained by EUS-guided fine-needle tissue acquisition: a prospective study.
Larghi A; Capurso G; Carnuccio A; Ricci R; Alfieri S; Galasso D; Lugli F; Bianchi A; Panzuto F; De Marinis L; Falconi M; Delle Fave G; Doglietto GB; Costamagna G; Rindi G
Gastrointest Endosc; 2012 Sep; 76(3):570-7. PubMed ID: 22898415
[TBL] [Abstract][Full Text] [Related]
54. Clinical outcome and long-term survival of 150 consecutive patients with pancreatic neuroendocrine tumors: A comprehensive analysis by the World Health Organization 2010 grading classification.
Deng BY; Liu F; Yin SN; Chen AP; Xu L; Li B
Clin Res Hepatol Gastroenterol; 2018 Jun; 42(3):261-268. PubMed ID: 29307515
[TBL] [Abstract][Full Text] [Related]
55. Prognostic Factors for Locoregional Recurrence in Neuroendocrine Tumors of the Rectum.
Tsang ES; McConnell YJ; Schaeffer DF; Yin Y; Speers CH; Kennecke HF
Dis Colon Rectum; 2018 Feb; 61(2):187-192. PubMed ID: 29337773
[TBL] [Abstract][Full Text] [Related]
56. Curative Surgery and Ki-67 Value Rather Than Tumor Differentiation Predict the Survival of Patients With High-grade Neuroendocrine Neoplasms.
Asano D; Kudo A; Akahoshi K; Maekawa A; Murase Y; Ogawa K; Ono H; Ban D; Tanaka S; Tanabe M
Ann Surg; 2022 Aug; 276(2):e108-e113. PubMed ID: 32941267
[TBL] [Abstract][Full Text] [Related]
57. Aberrant Expression of Long Non Coding RNA HOTAIR and De-Regulation of the Paralogous 13 HOX Genes Are Strongly Associated with Aggressive Behavior of Gastro-Entero-Pancreatic Neuroendocrine Tumors.
Di Mauro A; Scognamiglio G; Aquino G; Cerrone M; Liguori G; Clemente O; Di Bonito M; Cantile M; Botti G; Tafuto S; Tatangelo F
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34208964
[TBL] [Abstract][Full Text] [Related]
58. Applications of a novel tumor-grading-metastasis staging system for pancreatic neuroendocrine tumors: An analysis of surgical patients from a Chinese institution.
Yang M; Tan CL; Zhang Y; Ke NW; Zeng L; Li A; Zhang H; Xiong JJ; Guo ZH; Tian BL; Liu XB
Medicine (Baltimore); 2016 Jul; 95(28):e4213. PubMed ID: 27428224
[TBL] [Abstract][Full Text] [Related]
59. Early recurrence of well-differentiated (G1) neuroendocrine liver metastasis after curative-intent surgery: Risk factors and outcome.
Xiang JX; Zhang XF; Weiss M; Aldrighetti L; Poultsides GA; Bauer TW; Fields RC; Maithel SK; Marques HP; Pawlik TM
J Surg Oncol; 2018 Dec; 118(7):1096-1104. PubMed ID: 30261105
[TBL] [Abstract][Full Text] [Related]
60. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]